Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 How Long Does the Benefit of Biologics Last? An Update on Time To Relapse and Potential for Rebound of Biologic Agents for Psoriasis.

Literature DB >> 25346591

How Long Does the Benefit of Biologics Last? An Update on Time To Relapse and Potential for Rebound of Biologic Agents for Psoriasis.

Monique Kamaria¹, Wilson Liao², J Y Koo².

Abstract

The biologic agents vary considerably in terms of their long-term duration of effect. Using the definitions provided by the National Psoriasis Foundation Medical Board, the objective of this review was to compare all biologic agents with respect to time to relapse and potential for rebound. Overall, alefacept had the longest off-treatment benefit (29.9 weeks in Psoriasis Area and Severity Index [PASI] 75 responders), followed by ustekinumab (22 weeks), infliximab (19.5 weeks), adalimumab (18 weeks), etanercept (12.1 weeks in PASI 50 responders), and, lastly, efalizumab (9.6 weeks). Rebound was reported commonly for efalizumab (14%) and, extremely rarely, for etanercept (0.002%).

Entities: Chemical Disease Gene Species

Keywords: biologic agents; rebound; relapse

Year: 2010 PMID： 25346591 PMCID： PMC4205949

Source DB: PubMed Journal: Psoriasis Forum ISSN： 1089-3504

14 in total

1. Definitions of measures of effect duration for psoriasis treatments.

Authors: Kenneth B Gordon; Steven R Feldman; John Y M Koo; Alan Menter; Tara Rolstad; Gerald Krueger
Journal: Arch Dermatol Date: 2005-01

2. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.

Authors: Angela Moore; Kenneth B Gordon; Sewon Kang; Alice Gottlieb; Bruce Freundlich; H Amy Xia; Seth R Stevens
Journal: J Am Acad Dermatol Date: 2006-11-17 Impact factor: 11.527

3. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

Authors: Alan Menter; Steven R Feldman; Gerald D Weinstein; Kim Papp; Robert Evans; Cynthia Guzzo; Shu Li; Lisa T Dooley; Cynthia Arnold; Alice B Gottlieb
Journal: J Am Acad Dermatol Date: 2006-09-06 Impact factor: 11.527

4. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.

Authors: Alice B Gottlieb; Robert Evans; Shu Li; Lisa T Dooley; Cynthia A Guzzo; Daniel Baker; Mohan Bala; Colleen W Marano; Alan Menter
Journal: J Am Acad Dermatol Date: 2004-10 Impact factor: 11.527

5. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis.

Authors: Alice B Gottlieb; Umesh Chaudhari; Lisa D Mulcahy; Shu Li; Lisa T Dooley; Daniel G Baker
Journal: J Am Acad Dermatol Date: 2003-06 Impact factor: 11.527

6. Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study.

Authors: T F Tsai; M T Liu; Y H Liao; D Licu
Journal: J Eur Acad Dermatol Venereol Date: 2007-11-14 Impact factor: 6.166

4. A non-inferiority randomized controlled clinical trial comparing Unani formulation & psoralen plus ultraviolet A sol in chronic plaque psoriasis.

Authors: Neena Khanna; Tamanna Nazli; Khalid Mahmud Siddiqui; Mani Kalaivani
Journal: Indian J Med Res Date: 2018-01 Impact factor: 2.375

4 in total

How Long Does the Benefit of Biologics Last? An Update on Time To Relapse and Potential for Rebound of Biologic Agents for Psoriasis.

1. Definitions of measures of effect duration for psoriasis treatments.

2. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.

3. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

4. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.

5. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis.

6. Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study.

Review 7. Relapse, rebound, and psoriasis adverse events: an advisory group report.

8. Remittive effects of intramuscular alefacept in psoriasis.

9. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.

10. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

Review 1. Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances.

2. Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review.

3. The metabolomics of psoriatic disease.

4. A non-inferiority randomized controlled clinical trial comparing Unani formulation & psoralen plus ultraviolet A sol in chronic plaque psoriasis.